A collagen-based hydrogel containing tacrolimus for bone tissue engineering

Drug Deliv Transl Res. 2020 Feb;10(1):108-121. doi: 10.1007/s13346-019-00666-7.

Abstract

Bone tissue engineering aims to develop bone graft structure that can heal bone defects without using autografts or allografts. The current study was conducted to promote bone regeneration using a collagen type I hydrogel containing tacrolimus. For this purpose, different amounts of tacrolimus (10 μg/ml, 100 μg/ml, and 1000 μg/ml) were loaded into the hydrogel. The resulting drug-loaded hydrogels were characterized for their porosity, swelling capacity, weight loss, drug release, blood compatibility, and cell proliferation (MTT). For functional analysis, the developed hydrogel surrounded by a film made of gelatin and polycaprolactone (PCL) was administrated in the calvarias defect of Wistar rats. The results indicated that the hydrogel has a porosity of 89.2 ± 12.5% and an appropriate swelling, drug release, and blood compatibility behavior. The in vitro results indicated that the collagen hydrogel containing 1000 μg tacrolimus was adequate in terms of cell proliferation. Finally, in vivo studies provided some evidence of the potential of the developed hydrogel for bone healing.

Keywords: Bone; Collagen type I; Hydrogel; Osteogenesis; Tacrolimus (FK-506); Tissue engineering.

MeSH terms

  • Animals
  • Cell Line
  • Cell Proliferation / drug effects
  • Collagen Type I / chemistry*
  • Disease Models, Animal
  • Fracture Healing / drug effects*
  • Humans
  • Hydrogels
  • Male
  • Porosity
  • Rats
  • Rats, Wistar
  • Skull / drug effects
  • Skull / injuries*
  • Tacrolimus / administration & dosage*
  • Tacrolimus / chemistry
  • Tacrolimus / pharmacology
  • Tissue Engineering / methods*
  • Tissue Scaffolds

Substances

  • Collagen Type I
  • Hydrogels
  • Tacrolimus